Grifols (NASDAQ:GRFS) Stock Gets Price Target Cut from JPMorgan Chase & Co.

Grifols (NASDAQ:GRFS) had its price target trimmed by JPMorgan Chase & Co. from $10.00 to $9.00 in a research report report published on Monday,Benzinga reports. The firm currently has a neutral rating on the biotechnology company’s stock.

Several other research firms also recently issued reports on GRFS. Wall Street Zen downgraded Grifols from a “buy” rating to a “hold” rating in a report on Saturday, October 10th. Weiss Ratings raised Grifols from a “sell (d)” rating to a “sell (d+)” rating in a research note on Monday, August 17th. Finally, Zacks Research raised Grifols from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 7th. Two equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Reduce” and a consensus price target of $9.00.

Grifols Price Performance

GRFS opened at $8.12 on Monday. The company has a debt-to-equity ratio of 1.10, a current ratio of 2.37 and a quick ratio of 0.81. The stock has a market capitalization of $5.53 billion, a P/E ratio of 42.74, a price-to-earnings-growth ratio of 0.28 and a beta of 0.70. The company’s 50 day simple moving average is $7.59 and its 200-day simple moving average is $8.02. Grifols has a one year low of $6.96 and a one year high of $9.90.

Institutional Trading of Grifols

A number of institutional investors have recently bought and sold shares of the business. Flat Footed LLC lifted its stake in shares of Grifols by 26.5% in the 1st quarter. Flat Footed LLC now owns 1,372,394 shares of the biotechnology company’s stock valued at $11,007,000 after purchasing an additional 287,867 shares during the period. Tidal Investments LLC boosted its position in shares of Grifols by 9.8% in the 2nd quarter. Tidal Investments LLC now owns 1,233,082 shares of the biotechnology company’s stock worth $8,730,000 after purchasing an additional 109,612 shares during the last quarter. Royal Bank of Canada boosted its position in shares of Grifols by 15.4% in the 1st quarter. Royal Bank of Canada now owns 785,703 shares of the biotechnology company’s stock worth $6,301,000 after purchasing an additional 104,850 shares during the last quarter. Hennion & Walsh Asset Management Inc. boosted its position in shares of Grifols by 13.8% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 592,173 shares of the biotechnology company’s stock worth $4,193,000 after purchasing an additional 72,037 shares during the last quarter. Finally, Quantinno Capital Management LP grew its stake in shares of Grifols by 42.0% during the first quarter. Quantinno Capital Management LP now owns 352,798 shares of the biotechnology company’s stock worth $2,829,000 after purchasing an additional 104,418 shares during the period.

About Grifols

Grifols SA is a global healthcare company headquartered in Barcelona, Spain, specializing in plasma-derived medicines and diagnostic technologies. The company develops, manufactures and markets therapies made from human plasma, including immunoglobulins, albumin and coagulation factors used to treat immune deficiencies, bleeding disorders and other chronic conditions.

Grifols operates a vertically integrated plasma business that includes plasma donation centers, collection and fractionation facilities, research and development, manufacturing and distribution.